West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift

West Pharmaceutical Services delivered a strong 2Q26, beating on both revenue ($872.3M, +13.8% YoY) and EPS ($2.37, +$0.29 vs. consensus).

WST raised full-year guidance to $3.345–$3.380B in sales and $8.85–$9.05 in EPS, reflecting confidence in sustained double-digit organic growth and margin expansion.

High-Value Product components and biologics drove mix shift, with HVP now 49% of revenue and biologics up 29% organically, supporting durable margin gains.

Valuation remains rich at 41x forward earnings, but the premium is justified by high-quality compounding, visible growth pillars, and conservative guidance.

West Pharmaceutical Services, Inc. ( WST ) delivered a clean beat this week. 2Q26 adjusted EPS came in at $2.37, a $0.29 beat over the consensus, with revenue managing to hit $872.3 million. That revenue figure is up 13.8% YoY and also